The classification of Cough Suppressant Drugs is based on their ability to reduce coughing in animal models that lack airway pathophysiology. This classification is not comprehensive and includes many cough suppressants that also decrease cough sensitivity in healthy individuals. Cough suppressants are recommended only when they have been shown to be effective in double-blind, placebo-controlled studies in humans with respiratory pathology.
Benzoic acid esters are anesthetics used to suppress cough reflexes. They should never be taken long-term. They work on the medullar part of the brain and cause alterations in brain function. Benzoic acid esters may also cause other effects. If used long-term, they can alter brain function. Therefore, patients should always consult their physician before taking these drugs.
The global cough suppressant drugs market size was valued at US$ 1100.4 Mn in 2021 and is expected to witness a CAGR of 3.7% during the forecast period (2022 – 2028).
Get Sample PDF Copy (Including Full TOC, List of Tables & Figures, Chart) @
https://www.coherentmarketinsights.com/insight/request-sample/2427
Continuous approvals and launch of new cough suppressant drugs and high prevalence of cough is projected to drive the market growth
For instance, in March 2018, Perrigo Company plc. received the FDA approval for the brand OTC equivalent of Mucinex DM Maximum Strength (Guaifenesin and Dextromethorphan Hydrobromide Extended-release Tablets, 1200 mg/60 mg). Mucinex DM Maximum Strength is indicated to control coughs and to break up mucus, making coughs more productive.
Growing prevalence of cough is again projected to be a major factor for increasing demand for cough suppressant drugs, which drives the market growth. For instance, according to the data published by the National Center for Biotechnology Information in 2014, cough is the most common reason for visits to primary care physicians globally, accounting for around 8% of all consultations. According to the same source, the annual prevalence of cough in the general population is reported as approximately 10–33% globally.
North America is expected to hold leading position, due to frequent approvals of new cough suppressant drugs by FDA
North America cough suppressant market is expected to show good growth over the forecast period, due to frequent approvals to novel drugs by the FDA. For instance, in 2015, Vernalis plc and Tris Pharma Inc. received the U.S. Food and Drug Administration (FDA) approval for the New Drug Application (NDA) for Tuzistra XR (codeine polistirex and chlorpheniramine polistirex) extended-release oral suspension, CIII (DEA Schedule III). Tuzistra XR is a codeine-based extended-release oral suspension for cough-cold treatment.
Key players in the market are involved in strategic mergers and partnerships, in order to develop, produce, and sell novel cough suppressant drugs and to gain major market share.
For instance, in 2015, Tris Pharma, Inc. entered into a license, supply, and distribution agreement with Pfizer Consumer Healthcare (a part of Pfizer Inc.). According to the agreement, Pfizer Consumer Healthcare will commercialize Tris’ extended release dextromethorphan cough syrup under the Robitussin Brand. In exchange, Tris will provide the U.S. branded rights to its protected intellectual property for an extended release dextromethorphan formulation to Pfizer Consumer Healthcare and Tris will receive an upfront payment, milestone payments, and sales-based royalties.
Various new players are entering market by adopting growth strategies such as partnership. For instance, in November 2018, Aytu BioScience, Inc., a specialty pharmaceutical company, entered into the cough suppressant drugs market with an exclusive license of FDA-approved Tuzistra XR from Tris Pharma Inc. Along with Tuzistra XR, Aytu BioScience, Inc. also has a licensed complementary antitussive product with pending FDA approval.
However, strict regulations against the use of cough suppressant is projected to affect the global cough suppressant drugs market growth over the forecast period.
For instance, in February 2018, the Therapeutic Goods Administration reclassified codeine as prescription only medicine in Australia, which was previously available as over-the-counter medication. This reclassification was made, as regular use of medicines containing codeine may lead to its addiction.
Get PDF Brochure @
https://www.coherentmarketinsights.com/insight/request-pdf/2427
Regional Outlook:
The research divides the global Cough Suppressant Drugs market into segments based on various variables, as well as a geographic segmentation. This segmentation was carried out in order to gain thorough and trustworthy information about the global Cough Suppressant Drugs market. As global parts, the study looks at Latin America, North America, Asia Pacific, Europe, and the Middle East and Africa.
Method of Research:
For the time frame 2022-2028, the market research team used Porter’s Five Force Model to examine the Global Cough Suppressant Drugs Market demand. In addition, a thorough SWOT analysis is carried out to help the reader make more informed decisions about the Global Cough Suppressant Drugs Market demand. We used both primary and secondary data collection techniques. In addition, for a thorough analysis of the market, the data analysts used publicly available tools such as annual accounts, SEC filings, and white papers. The approach to analysis clearly reflects the goal of having it evaluated against various metrics in order to provide a comprehensive view of the market.
Key players operating in the global cough suppressant drugs market include Perrigo Company plc, Vernalis plc, Tris Pharma Inc., Pfizer Inc., Aytu BioScience, Inc., Acella Pharmaceuticals LLC, Mayne Pharma Inc., Taro Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Aurobindo Pharma Ltd, and GlaxoSmithKline plc.
Report covers:
◘ Comprehensive research methodology of Global Cough Suppressant Drugs Market.
◘ This report also includes detailed and extensive market overview with gap analysis, historical analysis & key analyst insights.
◘ An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
◘ Analysis of regional regulations and other government policies impacting the Global Cough Suppressant Drugs Market.
◘ Insights about market determinants which are stimulating the Global Cough Suppressant Drugs Market.
◘ Detailed and extensive market segments with regional distribution of forecasted revenues
◘ Extensive profiles and recent developments of market players
Buy This Complete Business Report @
https://www.coherentmarketinsights.com/insight/buy-now/2427
Table of Contents with Major Points:
Global Cough Suppressant Drugs Professional Survey Report Report 2022, Forecast to 2028
1 Market Overview Cough Suppressant Drugs Definition
1.1 Cough Suppressant Drugs Definition
1.2 Cough Suppressant Drugs Segment by Type
1.3 Market Analysis by Application
1.4 Global Cough Suppressant Drugs Market Comparison by Regions (2022-2028)
1.5 Market Dynamics
1.6 Coronavirus Disease 2019 (Covid-19): Cough Suppressant Drugs Industry Impact
…
2 Global Cough Suppressant Drugs Market Competition by Manufacturer
3 Analysis of Cough Suppressant Drugs Industry Key Manufacturers
4 Global Cough Suppressant Drugs Market Size Categorized by Regions
5 North America Cough Suppressant Drugs Market Size Categorized by Countries
6 Europe Cough Suppressant Drugs Market Size Categorized by Countries
7 Asia-Pacific Cough Suppressant Drugs Market Size Categorized by Countries
8 South America Cough Suppressant Drugs Market Size Categorized by Countries
9 Middle East and Africa Cough Suppressant Drugs Market Size Categorized by Countries
10 Global Cough Suppressant Drugs Market Segment by Type
11 Global Cough Suppressant Drugs Market Segment by Application
12 Market Forecast for Cough Suppressant Drugs
13 Cough Suppressant Drugs Related Market Analysis
14 Research Findings and Conclusion
….
Track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global Cough Suppressant Drugs Market. To elaborate the concepts more briefly, data is represented through graphical and table format. Requirements of customers are collected by examining the reviews from numerous industry experts.
About Coherent Market Insights
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837